cintirorgon   Click here for help

GtoPdb Ligand ID: 10045

Synonyms: compound 32J [WO2016201225A1] | LYC-55716 | LYC55716
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Cintirorgon (LYC-55716) is a first-in-class, oral, selective RORγ agonist that is being developed by Lycera as a novel immuno-oncology agent. It is one of the chemical structures claimed in Lycera's patent WO2016201225A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 101.52
Molecular weight 603.12
XLogP 7.19
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES FC(Oc1cc(F)cc(c1)c1ccc2c(c1)N(CC(O2)CC(C(=O)O)(C)C)S(=O)(=O)c1cccc(c1)C(F)(F)F)F
Isomeric SMILES FC(Oc1cc(F)cc(c1)c1ccc2c(c1)N(C[C@@H](O2)CC(C(=O)O)(C)C)S(=O)(=O)c1cccc(c1)C(F)(F)F)F
InChI InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1
InChI Key GULSIMHVQYBADX-FQEVSTJZSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 1 and 1/2 clinical trials testing LYC-55716 are recruiting patients (August 2018). Phase 1 NCT03396497 is evaluating LYC-55716 plus the checkpoint inhibitor pembrolizumab in NSCLC, whereas Phase 1/2 NCT02929862 will evaluate LYC-55716 as a monotherapy in a selection of locally advanced or metastatic solid tumours that are considered the most likely to be responsive to RORγ agonist therapy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
RORγ is a nuclear receptor transcription factor that acts as an immune cell master control switch. Activation of this switch by RORγ agonists mediates improved immune cell function and decreases immunosuppressive mechanisms, actions which synergise to bring about enhanced tumour cell killing.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02929862 Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer Phase 1/Phase 2 Interventional Lycera Corp.
NCT03396497 Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Phase 1 Interventional Lycera Corp.